Ann Marie L. Ogden - Concepedia

Concepedia

Author

Ann Marie L. Ogden

Eli Lilly (United States)

Also Known As

A. M. L. OGDEN, A.M Ogden, A.M. Ogden, A.M.L. Ogden, Ann M. Ogden, Ann Marie L. Ogden, Ann Marie Ogden, Ann Ogden

28

Publications

1.2K

Citations

16

H-Index

44

Concepts

All Affiliations

Eli Lilly (United States)University of Bristol Eli Lilly (Spain)Therapure Biopharma (Canada)Eli Lilly (United Kingdom)

AM

About

Ann Marie L. Ogden is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	892
2	Social Sciences	4	4	144
3	Natural Sciences	3	3	109
4	Health Sciences	1	1	38
5	Anesthesia	1	1	21

Ann Marie L. Ogden

×

18

Publications

1.2K

Citations

16

H-Index

	Year	Citations
Kainate receptors are involved in synaptic plasticity Zuner A. Bortolotto, Vernon R. J. Clarke, Caroline M. Delany, Nature Synaptic PlasticityNeuromodulationSynaptic TransmissionNeurotransmissionNeuroscience	1999	323
Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro Andrew Alt, Brianne Weiss, Ann Marie L. Ogden, Neuropharmacology Pharmacological CharacterizationGlutamatergic AgonistsMedicineFunctional SelectivityNeurotransmitter	2004	123
LY503430, a Novel α-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Potentiator with Functional, Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson’s Disease Tracey K. Murray, Katherine Whalley, Christine S. Robinson, Journal of Pharmacology and Experimental Therapeutics	2003	105
Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist Julia C. A. More, Robert Nisticò, Nigel P. Dolman, Neuropharmacology Molecular PharmacologyBiochemistryFunctional SelectivityMedicineMechanism Of Action	2004	100
Pharmacological Characterization of the Competitive GLUK5 Receptor Antagonist Decahydroisoquinoline LY466195 in Vitro and in Vivo Brianne Weiss, Andrew Alt, Ann Marie L. Ogden, Journal of Pharmacology and Experimental Therapeutics	2006	74
5-Aryl-3-(alkylthio)-4H-1,2,4-triazoles as selective antagonists of strychnine-induced convulsions and potential antispastic agents John M. Kane, Michael A. Staeger, Christopher R. Dalton, Journal of Medicinal Chemistry	1994	51
Ethyl (3<i>S</i>,4a<i>R</i>,6<i>S</i>,8a<i>R</i>)-6-(4-Ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso- quinoline-3-carboxylic Ester: A Prodrug of a GluR5 Kainate Receptor Antagonist Active in Two Animal Models of Acute Migraine Sandra Filla, Mark A. Winter, Kirk W. Johnson, Journal of Medicinal Chemistry Diethyl EsterPharmacotherapyExperimental Pharmacology4-Ethoxycar- Bonylimidazol-1-ylmethylMolecular Pharmacology	2002	51
ACET is a highly potent and specific kainate receptor antagonist: Characterisation and effects on hippocampal mossy fibre function Sheila Amici-Dargan, Vernon R. J. Clarke, Gregory M. Alushin, Neuropharmacology NeurophysiologyNeuroanatomyMedicinePhysiologyNeurotransmitter	2008	50
A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors Norton P. Peet, Nelsen L. Lentz, Mark W. Dudley, Journal of Medicinal Chemistry Adenosine ReceptorsAltmetric Attention ScorePharmacotherapyNovel SynthesisNew Binding Mode	1990	47
LY339434, a GluR5 kainate receptor agonist Ben G. Small, J W Thomas, Mark I. Kemp, Neuropharmacology Molecular PharmacologyMolecular PhysiologyG Protein-coupled ReceptorMedicinePhysiology	1998	45

Page 1